Press "Enter" to skip to content

FDA permits marketing of first medical device for treatment of ADHD

FDA permits marketing of first medical device for treatment of ADHD

Also Read:   Mylan Initiates Voluntary Nationwide Recall of Three Lots of Nizatidine Capsules, USP, Due to the Detection of Trace Amounts of NDMA (N-Nitrosodimethylamine) Impurity Found in the Active Pharmaceutical Ingredient Manufactured by Solara Active Pharma Sciences Limited